Introduction
============

Assessing the cost-effectiveness of therapeutic interventions is increasingly crucial for health decision-making. Spontaneous bacterial peritonitis (SBP) is one of the major complications of liver cirrhosis. The use of albumin in conjunction with antibiotics has been shown to be effective through clinical trials \[[@B1]\].

Methods
=======

A decision tree (TreeAge®) (Figure [1](#F1){ref-type="fig"}) was populated from published sources for clinical, cost and epidemiologic variables. The perspective taken was that of the US payer. The robustness of the model was checked using one-way and probabilistic sensitivity analyses. The clinical course was followed for 3 months or until death. Total medical costs and quality-adjusted life years (QALYs) \[[@B2]\] were calculated.

![**Structure of decision tree for patients with SBP**.](cc14433-1){#F1}

Results
=======

Total costs were decreased when using albumin, and the improved survival resulted in an additional QALY for patients on albumin, decreasing the cost per QALY. See Table [1](#T1){ref-type="table"} and Figure [2](#F2){ref-type="fig"}.

###### 

results of the cost-effectiveness model.

  Treatment               QALYs   Total medical costs (\$)   Total costs/ QALY (\$)
  ----------------------- ------- -------------------------- ------------------------
  Antibiotics + albumin   2.45    7,628                      3,111
  Antibiotics             1.48    7,682                      5,182

![**Cost-effectiveness acceptability across range of WTP**.](cc14433-2){#F2}

Conclusion
==========

The use of albumin in the treatment of SPB is cost-effective.
